marijuana stocks news

GW Pharmaceuticals to Present at the Leerink 2015 Global Healthcare Conference

LONDON, Feb. 5, 2015 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPH) (GWP.L) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Leerink 2015 Global Healthcare Conference to be held at the Waldorf Astoria Hotel in New York City on Wednesday, 11 February, 2015 at 3:30 p.m. EST.

A live audio webcast of the presentation will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. GW is also advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R), which is in Phase 2/3 clinical development for the treatment of Dravet syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Lennox-Gastaut syndrome. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

.

Contact:
GW Pharmaceuticals plc
(Today) +44 20 3727 1000
Stephen Schultz, VP Investor Relations (U.S.)
917 280 2424 / 401 500 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen (UK)
+ 44 20 3727 1000
Robert Stanislaro (U.S.)
212 850 5657
Trout Group, LLC (U.S. investor relations)
Todd James / Chad Rubin
646 378 2900

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Fire & Flower Holdings Corp. (FFLWF) Announces Exercise of Series A-3 Warrants by Alimentation Couche-Tard

Fire & Flower Announces Exercise of Series A-3 Warrants by Alimentation Couche-Tard…

Aphria Inc. (APHQF) Signs Agreement with AGLC to Supply Adult-Use Cannabis to Alberta

Aphria Signs Agreement with AGLC to Supply Adult-Use Cannabis to Alberta Aphria…

 Koios Beverage Corp. (KBEVF) Appoints Former Molson Coors Global Brand Director Josh Luman to its Board of Directors

Koios Appoints Former Molson Coors Global Brand Director Josh Luman to its…

Canopy Growth Corporation (CGC) LAUNCHES EXPANDED PRODUCT PORTFOLIO FOR THE QUEBEC MARKET

CANOPY GROWTH LAUNCHES EXPANDED PRODUCT PORTFOLIO FOR THE QUEBEC MARKET Canopy Growth…